PyroMark Systems for Verification and Validation of NGS and Other Genomewide Screening Results



In this webinar, Gerald Schock will discuss the use of Pyrosequencing technology for verification and validation of NGS and other genomewide screening results. NGS and hybridization arrays unlock genomewide information and identify targets whose biological relevance must be experimentally demonstrated. Systematic verification and validation of such data typically involve increased sample numbers, so cost-effective techniques for analyzing several hundreds of samples with high resolution and sensitivity are essential.

QIAGEN’s PyroMark platforms are ideally suited to analyze short- to medium-length sequences quantitatively with high accuracy. Compared to other widely used validation technologies, Pyrosequencing delivers both sequence information as well as highly sensitive quantification results. This technology has already been used in several studies to validate somatic mutation or methylation data.

The presentation will focus on the following topics
  • Pyrosequencing technology and workflow
  • Comparison to other validation technologies such as Sanger sequencing and real-time PCR
  • Latest advances in instruments, chemistry, and software

Dr. Gerald Schock, Associate Director PyroMark, QIAGEN GmbH

Gerald Schock

Dr. Gerald Schock is Associate Director for QIAGEN’s Pyrosequencing product line. Dr. Schock studied Biology and Biochemistry at the University of Mainz, Germany and at the University College of Wales, Aberystwyth, UK. He joined QIAGEN after receiving his Ph.D. in 1996, and has held positions in Sales, Regional Marketing, and Global Marketing, where he built up the epigenetics portfolio before assuming responsibility for the Life Science Pyrosequencing portfolio.